Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Kymab Limited is currently managing 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 5 distinct examiners, which indicates that no two pending matters are being reviewed by the same person. This one-to-one distribution requires the applicant to adapt to five different examiner styles and perspectives simultaneously.
The portfolio is also spread across 5 distinct art units, suggesting that the company's biotechnological innovations span a variety of specialized classifications. OGUNBIYI, OLUWATOSIN A is the busiest examiner for this portfolio and is currently overseeing 1 busiest examiner pending office action. This means that OGUNBIYI, OLUWATOSIN A is responsible for 1 of the 5 pending office actions currently active.
Managing 5 pending office actions across 5 distinct art units and 5 distinct examiners presents a significant coordination challenge. The applicant must address the unique requirements of each art unit while responding to the specific feedback of each examiner. Since the busiest examiner, OGUNBIYI, OLUWATOSIN A, only handles 1 busiest examiner pending action, the overall progress of the portfolio depends on the successful resolution of five independent examination processes.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (40%) |
| Double-patenting only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OGUNBIYI, OLUWATOSIN A | 1 | 63.8% | +41.2% |
| JOHNSON, TIRONE DEREK | 1 | 0.0% | +0.0% |
| ROONEY, NORA MAUREEN | 1 | 60.5% | +23.4% |
| LI, RUIXIANG | 1 | 59.5% | +18.7% |
| SINGH, ANOOP KUMAR | 1 | 43.2% | +67.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18634191 | PHARMACEUTICAL FORMULATIONS CONTAINING ANTI-OX40L ANTIBODIES | JOHNSON, TIRONE DEREK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18592425 | ANTI-PD-L1 AND IL-2 CYTOKINES | ROONEY, NORA MAUREEN | 42d overdue |
| 16905537 | Animal Models and Therapeutic Molecules | SINGH, ANOOP KUMAR | 22d |
| 18713540 | Antibodies for Use as Therapeutics Against Bacterial Infections | OGUNBIYI, OLUWATOSIN A | — |
| 18510228 | TREATMENT OF PD-L1 NEGATIVE OR LOW EXPRESSING CANCER WITH ANTI-ICOS ANTIBODIES | LI, RUIXIANG | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1675 | 1 |
| 1641 | 1 |
| 1674 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18713540 | Antibodies for Use as Therapeutics Against Bacterial Infections | OGUNBIYI, OLUWATOSIN A | 1645 | §112 | Non-Final OA | — | Pending | May 24, 2024 |
| 18634191 | PHARMACEUTICAL FORMULATIONS CONTAINING ANTI-OX40L ANTIBODIES | JOHNSON, TIRONE DEREK | 1675 | §102§103§112DP | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18592425 | ANTI-PD-L1 AND IL-2 CYTOKINES | ROONEY, NORA MAUREEN | 1641 | DP | Final Rejection | 42d overdue | Pending | Feb 29, 2024 |
| 18510228 | TREATMENT OF PD-L1 NEGATIVE OR LOW EXPRESSING CANCER WITH ANTI-ICOS ANTIBODIES | LI, RUIXIANG | 1674 | §112 | Non-Final OA | — | Pending | Nov 15, 2023 |
| 16905537 | Animal Models and Therapeutic Molecules | SINGH, ANOOP KUMAR | 1632 | §112DP | Final Rejection | 22d | Pending | Jun 18, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKymab Limited has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Oluwatosin A Ogunbiyi has the most, with 1 of Kymab Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
